In a prospective cohort study, Light identified clinically accessible site mutations, such as BRAF V600E mutations, NF1 mutations, and hypermutation indicating the efficacy of immune checkpoint inhibitors, in three pediatric cancer patients with germline TP53 pathogenic mutations (Light et al. 2023). Here, BRAF is linked to cancer.